Murrell DF, Patsatsi A, Stavropoulos P, et al. - Findings demonstrate safety as well as effectiveness of rilzabrutinib [a Bruton tyrosine kinase (BTK) inhibitor] alone or with much lower corticosteroid doses than usual for treating pemphigus. Thus, BTK inhibition represents a promising treatment choice for patients suffering from pemphigus.

• This is the first trial to test a new drug called rilzabrutinib in 27 patients with different severity of pemphigus.

• Patients received oral rilzabrutinib for 12 weeks, then followed up for another 12 weeks.

• A rapid and sustained improvement in pemphigus disease activity measures was achieved with rilzabrutinib use (which can be taken alone or together with low doses of corticosteroids).

• Patients well-tolerated it and experienced improvement in their quality of life.